Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

Mutations in the interleukin-7 receptor (IL7R) or the Janus kinase 3 (JAK3) kinase occur frequently in T-cell acute lymphoblastic leukemia (T-ALL) and both are able to drive cellular transformation and the development of T-ALL in mouse models. However, the signal transduction pathways downstream of...

Descripción completa

Detalles Bibliográficos
Autores principales: Degryse, S, de Bock, C E, Demeyer, S, Govaerts, I, Bornschein, S, Verbeke, D, Jacobs, K, Binos, S, Skerrett-Byrne, D A, Murray, H C, Verrills, N M, Van Vlierberghe, P, Cools, J, Dun, M D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843905/
https://www.ncbi.nlm.nih.gov/pubmed/28852199
http://dx.doi.org/10.1038/leu.2017.276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843905/
https://www.ncbi.nlm.nih.gov/pubmed/28852199
http://dx.doi.org/10.1038/leu.2017.276

Ejemplares similares